Forum Replies Created
-
Hi Joy,
I suspect Joan picked it for GT2 with the Ribavirin being cheaper than Daclatasvir and still giving “acceptable” clearance rates and “minimal” sides.
Of course this depends on who’s wallet is defining “acceptable” and “minimal”, doesn’t it?
For the GT4-6, I’m not really certain as Peg costs are usually fairly high but maybe they have a stockpile of Peg left over and figure that upsetting small numbers of a minority group of patients are better that antagonising the three main GTs in Australia?
Hopefully the finalised recommendations will include Riba and Peg free subsets in which case it would probably be advisable to make sure your doctor determines you as unsuitable for these old meds if in one of those GTs.
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
Thanks for the update, Cindi!
Just great to hear that J is doing so well. It will make a huge difference to his life to be able to clear the virus at his age.
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
Hi Life,
Good to hear you are doing so well. I think we are all “getting there”, or will.
Life wrote:I smell coffees, waffres and hot-dogs from a huge distance, I’ve been eating stuff I could not have dreamed of in years…
Ah, after six weeks I know this. Tonight was “Must…..not…..order……pizza…..mmmm…….cheese……No!” so we had salad. But tomorrow is New Year!!!!
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
No Alsdad, he’s the minister for health…..medications are for sick people, different department.
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
KP
dointime wrote:Just because I’m paranoid does not mean they are not out to get me.
dt
Uh, no. I was just spotting birds through the telescopic sights……..honest!
But now I understand your questions about longer treatment in the other threads. More details may help us to help you but in this case it sounds like you need expert advice.
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
Yes, particularly as these trials are set up to “prove” the various manufactured DAA pills that are now available instead of the APIs that I, and I believe you, are on.
But as you say it would be nice if we could put together some sort of database of off trial results for the more ad hoc amongst us. The world map with coloured pins sounded good but not sure how that has progressed?
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
LondonGirl wrote:have decided to go through Redemption.
This takes all the worry of supply chain integrity awayHave to agree LondonGirl,
The Doc’s organising of the Redemption trials must give huge confidence to both heppers and doctors who were concerned about generics both from a sourcing and quality point of view. This was a big factor in my decision to use the FixHepC buyers club when I stumbled onto the generics path three months ago. Set up by a well known Australian doctor with easily checkable veracity (yep, I did due diligence ;~} ) who was happy to front our national media and had set up a system of NATA level testing for each import we made was a huge confidence booster for me. But of course only available for Australian delivery unlike Redemption .
I must admit I would have liked to participate in these trials myself but it was early days then and my priority was to get treatment started asap based on my state of health. I can be very impatient when I decide a course of action.
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
Hi Rowan,
I’m on the same meds as you and the Riba will be the main culprit. Due to delays in arrival of the Riba I started on the Sof/Dac first and added the Riba 16 days later. Definitely noticed the difference and fairly similar sides to you. Lethargy, intermittent aches, lots of insomnia and leg cramps a couple of nights. No nausea but as LondonGirl suggests I do take the Riba with some fat. Full fat milk on my cereal and fruit in the morning and whatever I’m eating in the evening although if it is low/no fat I will have a glass of milk or chunk of cheese at the same time. Having said that, I do feel much better overall than pretreatment, both physically and psychologically.
…..and it looks like a chat with my specialist soon about the latest evidence!
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
Congratulations on achieving Undetected, jeanmarc!
It must be a huge relief after all the worrying about what the tests meant!
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
Geno1b4 wrote:When getting quotes from distributors in India I’ve found this one to be cheapest of three Harvoni generics, dunno why is that, hopefully it is not quality issue:
As it is also manufactured by Natco I would suspect (but obviously can’t confirm) it is coming off the same production line but with different packaging.
We need to remember that with such recent release (only a few weeks ago) the various manufacturers and distributors will be jostling for marketing advantage. Larger ones will have the advantage of volume to reduce prices but OTOH they will be better known and trusted so can charge a premium while smaller ones are the reverse. Then there will be “special introductory offers” to gain initial market share but if these result in the distributor risking running out of stock they will put their prices back up until they can restock. I suspect in six months or so the market will be more settled with “household name” brands charging a slight premium and the lesser known ones being slightly cheaper. This is marketing today!
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
Hi Vororo,
As with you, I don’t know what he actually said to accompany that slide. However my take was that he wasn’t stating that any particular one was real or not but instead claiming that if DAAs were more affordable there would be no need for people to go through the process that you just did of trying to determine which are genuine patent product, authorised generics, unauthorised generics or just counterfeits of one of these that didn’t contain correct amounts or possibly any APIs.
With cheaper prices that problem just goes away, much like with aspirin where you can purchase Disprin as the branded product or you can go anywhere in the world and purchase any aspirin product and be confident that you are getting what you paid for and that it will work as intended because there is no financial incentive (and probably a disincentive) to make a fake product.But as you say, until that happens, it is buyer beware.
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
I suspect there is little research on what you are asking as:
– It would require crosslabel trials which tend to be expensive.
– the standard treatment approach seems to be to use one NS5A inhibitor thoughout treatment and if that treatment fails to retreat preferably using another NS5A inhibitor that expresses itself via a different path if such an drug exists. This would apparently reduce any risk of resistance effecting the retreatment. I don’t know whether Dac and Led differ sufficiently to do that or whether they are entirely analogous.I’m not a scientist just an interested reader so the above is just my take on it.
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
Thanks Sabrecat,
That reminded me of a report I read the other week re G3. Basically their comments were that this genotype needs hitting asap with the new DAAs, try to increase metabolic rate, reduce fatty liver disease risks and keep monitoring even non cirrhosis patients post SVR. So not great news but important for us to know.
http://hepatitiscnewdrugs.blogspot.com.au/2015/12/hcv-genotype-3-wolf-in-sheeps-clothing.html
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
Thank you Sabrecat,
In many ways your stated feelings resonate with my quieter moments. My life seems to have changed greatly over the last six weeks but I am still unsure where it will lead and what will develop. I suspect it will take some time and I will need patience.
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
I agree that some variations may (probably will?) give the same outcome.
But using me as an example which past treatment fail should be selected? Interferon/riba or NS3/4/5? I had both in trial but wonder whether the outcome from both choices could be the same? Admittedly mine would be a small subset. And in Tim’s case possibly Inferferon/Riba may be considered close enough?……..but what about the case of someone who failed Harvoni (branded or generic), should the selection be for failing Sofosbuvir Xwks or failing NS3/4/5? How would that decision be arrived at? And would the outcome be the same for either?
Ouch Tim, that would be 3 jabs per week!
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
